Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-08
2011-11-29
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S058000, C514S179000
Reexamination Certificate
active
08067433
ABSTRACT:
The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant.
REFERENCES:
patent: 4512978 (1985-04-01), Inwood
patent: 4569935 (1986-02-01), Rosenberg et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 5411952 (1995-05-01), Kaswan
patent: 5474979 (1995-12-01), Ding et al.
patent: 5981607 (1999-11-01), Ding et al.
patent: 6254860 (2001-07-01), Garst
patent: 6331313 (2001-12-01), Wong et al.
patent: 6369116 (2002-04-01), Wong et al.
patent: 6677304 (2004-01-01), Di Napoli
patent: 6809077 (2004-10-01), Or et al.
patent: 6872705 (2005-03-01), Lyons
patent: 2003/0216431 (2003-11-01), Raut
patent: 2004/0151754 (2004-08-01), Ashton
patent: 2004/0152664 (2004-08-01), Chang et al.
patent: 2004/0180868 (2004-09-01), Mullally
patent: 2004/0259863 (2004-12-01), Eggenweiler et al.
patent: 2005/0059583 (2005-03-01), Acheampong et al.
patent: 2005/0112069 (2005-05-01), Beume et al.
patent: 2005/0112199 (2005-05-01), Padval et al.
patent: 2005/0192261 (2005-09-01), Jost-Price et al.
patent: 2005/0256081 (2005-11-01), Peyman
patent: 2005/0277584 (2005-12-01), Tien et al.
patent: 2006/0002963 (2006-01-01), Rabinovich-Guilatt et al.
patent: 2006/0003982 (2006-01-01), Williams et al.
patent: 2006/0122152 (2006-06-01), Peyman
patent: 2006/0148686 (2006-07-01), Xia et al.
patent: 2007/0225217 (2007-09-01), Chappell et al.
patent: 05310591 (1993-11-01), None
patent: WO 03/000289 (2003-01-01), None
patent: WO 2006/050965 (2004-05-01), None
patent: WO 2004/069267 (2004-08-01), None
patent: WO 2004/096216 (2004-11-01), None
patent: WO 2005/027839 (2005-03-01), None
Birnbaum et al., “Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study” Transplantation Apr. 27, 2005;79(8):964-968.
Lim et al., “Serpiginous choroiditis” Surv Ophthalmol. May-Jun. 2005;50(3):231-244.
Menezo et al., “Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis” Clin Exper Ophthalmol Feb. 2005;33(1):16-21.
Nguyen et al., “Tyndallometry in monitoring therapy of sympathetic ophthalmia” Klin Monatsbl Augenheilkd. Jan. 1994;204(1):33-36.
Sajjadi et al. “Low dose cyclosporine-A therapy in Behcet's Disease” J Ocul Pharmacol. 1994 Fall;10(3):553-560.
Sra et al., “New trends in ocular allergy” Clin Surg Ophthalmol. Apr. 2005;23(4):136-142.
Utech et al., “Treatment of Graves Ophthalmopathy with Cyclosporin A Alone and in Combination with Corticosteroids” Acta Endocrinol Suppl (Copenh). 1985 08(267):72.
Zierhut et al., “Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis” Ophthalmologe. Jul. 2001;98(7):647-651.
Extended European Search Report for European Application No. EP 10 00 1901; Dated Jul. 1, 2010.
Mizoguci et al., “Cyclosporin Ointment for Psoriasis and Atopic Dermatitis,”The Lancet339(8801): 1120, 1992.
Al-Torbak et al., “Deep Corneal Neovascularization After Implantation With Intrastromal Corneal Ring Segments” Am J Ophthalmol Nov. 2005;140(5):926-927.
Anderson and Regillo “Ocular manifestations of graft versus host disease” Curr Opin Ophthalmol. Dec. 2004;15(6):503-507.
Chung et al., “Confocal Microscope Findings in a Case of Delayed-onset Bilateral Diffuse Lamellar Keratitis after Laser In Situ Keratomileusis,” J. Cataract Refract. Surg. 28:1467-1470, 2002.
Hakin et al., “Sympathetic Ophthalmia: Visual Results with Modern Immunosuppressive Therapy,” Eye:453-455,1992.
Kosrirukvongs et al., “Vernal Keratoconjunctivitis in Thailand” Asian Pac J Allergy Immunol Mar. 2003;21(1):25-30.
Mills et al., “Effect of Immunosuppression on Outcome Measures in a Model of Rat Limbal Transplantation” Invest Ophthalmol Vis Sci. Mar. 2002;43(3):647-655.
Muhaya et al., “Behçet's Disease in Japan and in Great Britain: a Comparative Study” Ocul Immunol Inflamm Sep. 2000;8(3):141-148.
Nussenblatt et al., “Randomized, Double-Masked Study of Cyclosporine Compared to Prednisolone in the Treatment of Endogenous Uveitis” Am. J. Opthalmol. 112:138-146, 1991.
Ogawa et al., “Successful Treatment of Dry Eye in Two Patients With Chronic Graft-Versus-Host Disease With Systemic Administration of FK506 and Corticosteroids” Cornea May 2001:20(4):430-434.
Perry et al., “Topical Cyclosporine A 0.5% as a Possible New Treatment for Superior Limbic Keratoconjunctivitis” Ophthalmology. Aug. 2003;110(8):1578-1581.
Rao, “Treatment of Herpes Simplex Virus Stromal Keratitis Unresponsive to Topical Prednisolone 1% With Topical Cyclosporine 0.05%” Am J Ophthalmol. Apr. 2006;141(4):771-772.
Wehrly et al., “Cytomegalovirus Keratitis After Penetrating Keratoplasty” Cornea. Nov. 1995;14(6):628-633.
Whitcup et al., “Topical Cyclosporine Inhibits Mast Cell-Mediated Conjunctivitis,” Invest. Opthalmol. Vis. Sci. 37:2686-2693, 1996.
Williams et al., “A Comparison of the Effects of Topical Cyclosporine and Topical Steroid on Rabbit Corneal Allograft Rejection” Transplantation. Mar. 1985;39(3):242-244.
Zhang et al., “The Effect of Corticosteroid and Cyclosporin A on Murine Corneal Allograft Rejection” Graefes Arch Clin Exp Ophthalmol. Jun. 2000;238(6):525-530.
International Search Report for PCT/US2006/043493, Dated: Jul. 12, 2007.
Office Action (U.S. Appl. No. 11/594,436), mailed Mar. 30, 2010.
Supplemental European Search Report for PCT/US2006/043493, Dated: Nov. 27, 2009.
Chappell Todd W.
Grau Daniel S.
Nichols M. James
Clark & Elbing LLP
Hartley Michael G
Samala Jagadishwar
Zalicus Inc.
LandOfFree
Methods, compositions, and kits for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods, compositions, and kits for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods, compositions, and kits for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304234